Sagimet Biosciences Future Growth
Future criteria checks 0/6
Sagimet Biosciences's earnings are forecast to decline at 26.1% per annum while its annual revenue is expected to grow at 78.2% per year. EPS is expected to decline by 11.6% per annum.
Key information
-26.1%
Earnings growth rate
-11.6%
EPS growth rate
| Biotechs earnings growth | 24.7% |
| Revenue growth rate | 78.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 02 May 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -167 | N/A | N/A | 4 |
| 12/31/2025 | N/A | -115 | N/A | N/A | 4 |
| 12/31/2024 | N/A | -59 | N/A | -58 | 5 |
| 12/31/2023 | 2 | -28 | -24 | -24 | N/A |
| 9/30/2023 | 2 | -27 | -24 | -24 | N/A |
| 6/30/2023 | N/A | -28 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -28 | -27 | -27 | N/A |
| 12/31/2022 | N/A | -30 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -24 | -22 | -22 | N/A |
| 12/31/2020 | N/A | -11 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGMT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SGMT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SGMT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SGMT is forecast to have no revenue next year.
High Growth Revenue: SGMT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if SGMT's Return on Equity is forecast to be high in 3 years time